Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
T. Koga, Kenichi Suda, Toshio Fujino, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 8, pp. 1321-1332
Open Access | Times Cited: 171

Showing 26-50 of 171 citing articles:

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer
Sun Min Lim, Toshio Fujino, Chulwon Kim, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 16, pp. 3004-3016
Open Access | Times Cited: 35
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Marina Salmón, Ruth Álvarez, Coral Fustero‐Torre, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 33
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
Atish Mohanty, Arin Nam, Saumya Srivastava, et al.
Science Advances (2023) Vol. 9, Iss. 41
Open Access | Times Cited: 32
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
Mariacarmela Santarpía, Giuliana Ciappina, Calogera Claudia Spagnolo, et al.
Translational Lung Cancer Research (2023) Vol. 12, Iss. 2, pp. 346-368
Open Access | Times Cited: 29
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
Yunkai Yang, Huan Zhang, Shanshan Huang, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 709-709
Open Access | Times Cited: 27
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1352-1370
Open Access | Times Cited: 9
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
Jinming Liu, Biao Zhang, Bingqian Huang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
KRAS G12C Mutations in NSCLC: From Target to Resistance
Alfredo Addeo, Giuseppe Luigi Banna, Alex Friedlaender
Cancers (2021) Vol. 13, Iss. 11, pp. 2541-2541
Open Access | Times Cited: 55
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry
Febe van Maldegem, Karishma Valand, Megan Cole, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 55
Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Junmin Zhang, Jilei Zhang, Qing Liu, et al.
Pharmacology & Therapeutics (2021) Vol. 229, pp. 108050-108050
Closed Access | Times Cited: 44
Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer
T. Koga, Kenichi Suda, Tetsuya Mitsudomi
Cancer Science (2022) Vol. 113, Iss. 3, pp. 815-827
Open Access | Times Cited: 35
More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C
Caressa Lietman, Melissa L. Johnson, Frank McCormick, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 205-217
Open Access | Times Cited: 32
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Zixi Wang, Yurou Xing, Bingjie Li, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 31
Targeting KRAS in Non-Small Cell Lung Cancer
E. Corral de la Fuente, M.E. Olmedo García, Ana Gómez Rueda, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 29
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi
Lung Cancer (2024) Vol. 194, pp. 107886-107886
Open Access | Times Cited: 7
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 6
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Jie Yang, Qiao-Li Wang, Guannan Wang, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Juan Bautista Blaquier, Andrés F. Cardona, Gonzalo Recondo
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 39
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Matthias Drosten, Mariano Barbacid
Molecular Oncology (2021) Vol. 16, Iss. 5, pp. 1057-1071
Open Access | Times Cited: 38
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
Shannon Zhang, Misako Nagasaka
Lung Cancer Targets and Therapy (2021) Vol. Volume 12, pp. 115-122
Open Access | Times Cited: 34
Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
Marc Cucurull, L. Notario, Montse Sánchez‐Céspedes, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 26
Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
Jingran Ji, Chongkai Wang, Marwan Fakih
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 747-756
Open Access | Times Cited: 26
Combined KRASG12Cand SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lu, Sabine Jurado, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 14

Scroll to top